Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.